18p- syndrome and hypopituitarism

Henry G Artman, Colleen A Morris, A Dean Stock

Abstract
A patient is described with 18p- syndrome and hypopituitarism. This is the first patient with this syndrome who has been shown to benefit from growth hormone therapy. Patients with this syndrome should be considered for evaluation for hypopituitarism, if the quality of their lives would improve with an increase in stature.

(J Med Genet 1992;29:671-2)

Short stature has been associated with deletion of the short arm of chromosome 18. There have been two reported cases of growth hormone deficiency associated with 18p- syndrome. The first patient showed no response to growth hormone and the treatment was not undertaken for the second patient. Another abnormality of chromosome 18 is ring chromosome 18 and growth hormone deficiency has been described and treated successfully.

The aetiology of the growth hormone deficiency in 18p- syndrome is unknown although holoprosencephaly, described in 10% of cases with 18p-, is associated with growth hormone deficiency. We describe a patient with 18p- as the result of an 18;21 translocation who had pituitary hypoplasia, growth hormone deficiency, and a response to growth hormone therapy.

Case report
A 3 year 9 month old male was referred to the Department of Pediatrics, University of Nevada School of Medicine, for evaluation of poor growth. He was the product of a 33 year old gravida 2, para 2, 36 week pregnancy complicated by toxoaemia. The father was aged 35 at the time of the proband’s birth. The birth weight was 3175 g (50th centile) and birth length was 49 cm (25th centile). Head circumference at birth was 33.5 cm (approximately 20th centile). Problems in the newborn period included difficulty in sucking and absence of the rooting reflex. The patient has had persistent failure to thrive consisting of poor linear growth and weight gain beginning at 6 months of age. In addition he had developmental delay. He sat at 8 months and walked at 16 months. The first words were spoken at 17 months and sentences were first used at 31 months. Medical problems included chronic otitis media, pneumonia at the age of 2, and eczema of the lower extremities treated with topical steroids.

Chromosome studies obtained at 2½ years showed an 18;21 translocation resulting in an 18p deletion. Parental chromosome studies were normal. High resolution chromosome studies were performed at the age of 8 years in order to clarify the breakpoints (fig 1). The karyotype is 45,XY,-18,-21,+der(18)t(18;21)(p11.23;q11.2). This de novo translocation resulted in a partial deletion of the short arm of chromosome 18, including 18p11.23→18pter. Thyroid function tests showed normal values for total T4 of 6.7 μg/dl and T3 of 156 ng/dl. Bone age at 2½ years was interpreted as being one year delayed.

At the time of presentation (3 years 9 months), he was 86.5 cm in height, 4 SD below the mean. Head circumference was on the 50th centile. Weight was 11.4 kg, 2 SD below the mean. At re-evaluation aged 5 years 6 months, mild dysmorphic facial features were noted (fig 2). His interpupillary distance of 43 mm
was below the 3rd centile. He had peri-orbital fullness, a tent shaped upper lip, short philtrum, wide mouth, and micrognathia. The ears measured on the 90th centile and had mild lateral protrusion. The hands were less than the 3rd centile. There was bilateral fifth finger clinodactyly and hallux valgus. His feet also measured less than the 3rd centile. Elbows were hyperextensible and generalized hypoplasia was present. The third toe was set back on the right foot.

Bone age was delayed by two years. Serial growth measurements continued to show slow growth rate the next seven months despite discontinuation of topical steroids. His endocrine status showed thyroid function tests to be normal with an adjusted T4 of 10 μg/dl and a TSH of 1-4 IU/ml. Clonidine (150 μg/m²) and L-Dopa (250 mg) were used to stimulate growth hormone release. Only one sample had a significant increase in serum growth hormone: 8-4 ng/ml (normal response is greater than 10 ng/ml). The remainder of the samples obtained were less than 4 ng/ml. Insulin hypoglycaemia was induced. Serum cortisol increased in a normal fashion to 32-6 μg/dl at 45 minutes after 0-1 U/kg of regular insulin was intravenously administered. An MRI scan of the brain showed hypoplasia of the hypothalamus and pituitary gland. Dental enamel hypoplasia was diagnosed at 4 years and was treated by capping.

During the seven month observation period when no topical steroids were used, the patient grew at an average rate of 3-4 cm per year, which is more than 2 SD below the mean growth rate for his age. The patient was initially treated with 0-1 mg/kg of synthetic growth hormone (Protropin) subcutaneously three times per week. Because there was a slowing in catch up growth after 16 months of growth hormone therapy, the dosage regimen was changed to 0-05 mg/kg six times per week. Growth rate increased and has been at 8-5 cm per year, 2 SD above the mean (fig 3).

Psychometric evaluation performed at the age of 4 years 10 months showed a Stanford Binet score of 99 and specific learning disabilities in the area of visual motor integration.

Discussion

The 18p- syndrome is a well described entity. Patients usually have mental retardation, dental caries, dysmorphic facial features, and increased risk for autoimmune disorders.5 Short stature is a common feature and may be the result of growth hormone deficiency, although there have been only two such patients described. Of interest is the fact that midline structural defects have growth hormone deficiency as part of their continuum. Two defects associated with both 18p- syndrome and growth hormone deficiency are single central incisor and holoprosencephaly.6

One child reported by Leisti et al.7 did not respond to growth hormone therapy. This may be because of the age of the patient (12 years), the lower dose and less frequent administration (two per week), a less potent preparation of growth hormone (a pituitary extract), or the multifactorial cause of short stature in this syndrome.7 Our patient has a clear cut acceleration in linear growth and is now just under 2 SD below the mean in height. As in our patient, normal or borderline intelligence has been reported in two previous cases.6 The relatively mild manifestations of the 18p- syndrome in our patient may in part be the result of the small deletion of chromosome 18. In the patient described with ring 18 chromosome the location and extent of deletion was not determined. Although the patient was responsive to growth hormone therapy, hypopituitarism secondary to neonatal hypoxia could not be excluded aetologically.

In summary, we report here the third patient with 18p- and hypopituitarism. Patients with the 18p- syndrome should have an evaluation for growth hormone deficiency as the potential for replacement therapy may help to improve their quality of life.

18p- syndrome and hypopituitarism.

H G Artman, C A Morris and A D Stock

doi: 10.1136/jmg.29.9.671

Updated information and services can be found at:
http://jmg.bmj.com/content/29/9/671

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/